Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria
VRTX•Phase 2b results in AMKD populations
Sept. 22 (Reuters) - Vertex Pharmaceuticals Incorporated VRTX.O:
- Vertex announces positive results from phase 2b Amplified study of inaxaplin in additional populations of people with APOL1-mediated kidney disease (AMKD) and completion of enrollment in the phase 2/3 Amplitude trial
- Vertex Pharmaceuticals Incorporated - Inaxaplin reduces UACR by -42.7% at week 13 in AMKD with modest proteinuria
- Vertex Pharmaceuticals Incorporated - Inaxaplin reduces UACR by -17.3% at week 13 in AMKD with type 2 diabetes
- Vertex Pharmaceuticals Incorporated - Inaxaplin generally safe and well tolerated in both AMKD cohorts
Source text: ID:nBw7hv65ma
Further company coverage: VRTX.O
